drugset / Trial / NCT02522572
Quantitating the Impact of Plerixafor
Non-randomizedSequentialOpen-labelTreatment
Summary
The primary objective of this study is to conduct a proof of concept pilot study that will provide a preliminary evaluation of the safety of plerixafor alone or in combination with bortezomib on plasma cell mobilization, Human Leukocyte Antigen (HLA) antibody levels and toxicity profile in sensitized patients awaiting kidney transplantation. The secondary objective of this study is to conduct additional analyses of the study regimen on HLA antibody levels using multiple different assays and statistical analysis.
Timeline
- Start
- 2015-08
- Primary completion
- 2020-09
- Completion
- 2020-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | — | Intravenous |
| Subject | Plerixafor | Small molecule | — | Subcutaneous |
Indications
No indication recorded.